Tiotropium respimat® soft mist™ inhaler: A review of its use in chronic obstructive pulmonary disease

Drugs

Volumn 74, Issue 15, 2014, Pages 1801-1816

  Keating, Gillian M ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; IPRATROPIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE; SCOPOLAMINE DERIVATIVES; TIOTROPIUM;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRY POWDER INHALER; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MORTALITY; SOFT MIST INHALER; ADMINISTRATION, INHALATION; HUMANS; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; HUMANS; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 84922080128     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0307-4     Document Type: Article

References (76)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: updated 2014. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html (2014). Accessed 22 Sep 2014.
2. Barnes PJ. The pharmacological properties of tiotropium. Chest. 2000;117(2 Suppl):63S-6S.
3. Boehringer Ingelheim Limited. Spiriva (tiotropium) Respimat 2.5 micrograms, solution for inhalation: UK summary of product characteristics. 2014. http://www.medicines.org.uk/emc/medicine/20134/SPC/Spiriva+Respimat+2.5+micrograms+solution+for+inhalation/. Accessed 22 Sep 2014.
4. Boehringer Ingelheim Limited. Spiriva (tiotropium) 18 microgram inhalation powder, hard capsule: UK summary of product characteristics. 2013. http://www.medicines.org.uk/emc/medicine/10039. Accessed 22 Sep 2014.
5. Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs. 2012;72(2):273-300.
6. ® Soft Mist™ Inhaler. Int J Pharm. 2004;283(1-2):1-9.
7. Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;12(Suppl 1):S19-24.
8. ® Soft Mist™ inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18(3):273-82.
9. ® dry powder inhaler. J Aerosol Med. 2005;18(3):264-72.
10. Newman SP, Steed KP, Reader SJ, et al. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci. 1996;85(9):960-4.
11. ® Soft Mist™ inhaler. J Aerosol Med. 2007;20(1):7-12.
12. Medicines Evaluation Board. Public assessment report of the Medicines Evaluation Board in the Netherlands: Spiriva (tiotropium) Respimat 2.5 microgram, solution for inhalation. 2011. http://www.cbg-meb.nl/CBG/en/human-medicines/geneesmiddeleninformatiebank/default.htm. Accessed 22 Sep 2014.
13. Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva™): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999;64(6-7):457-64.
14. 3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol. 1994;45(5):899-907.
15. Disse B, Reichl R, Speck G, et al. BA 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 1993;52(5-6):537-44.
16. Tautermann CS, Kiechle T, Seeliger D, et al. Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor. J Med Chem. 2013;56(21):8746-56.
17. Takahashi T, Belvisi MG, Patel H, et al. Effect of BA 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med. 1994;150(6 Pt 1):1640-5.
18. Sykes DA, Dowling MR, Leighton-Davies J, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther. 2012;343(2):520-8.
19. ® in COPD patients. Respir Med. 2009;103(1):22-9.
20. ® Soft Mist™ Inhaler vs. ipratropium pMDI in COPD. Respir Med. 2008;102(1):32-41.
21. Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 μg via Respimat and 18 μg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med. 2010;104(2):228-36.
22. Hohlfeld JM, Sharma A, van Noord JA, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54(4):405-14.
23. ® SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis. 2010;5:197-208.
24. ® plus usual therapy in COPD patients. Respir Med. 2010;104(10):1460-72.
25. ® Soft Mist Inhaler™: findings from two dose-ranging studies in healthy men. Int J Chron Obstruct Pulmon Dis. 2008;3(3):397-403.
26. Asano K, Shikama Y, Shibuya Y, et al. Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro. Int J Chron Obstruct Pulmon Dis. 2008;3(4):781-9.
27. Asano K, Shikama Y, Shoji N, et al. Tiotropium bromide inhibits TGF-β-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro. Int J Chron Obstruct Pulmon Dis. 2010;5:277-86.
28. Powrie DJ, Wilkinson TMA, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J. 2007;30(3):472-8.
29. Holownia A, Mroz RM, Skopinski T, et al. Tiotropium increases PPARγ and decreases CREB in cells isolated from induced sputum of COPD patients. Adv Exp Med Biol. 2013;756:9-14.
30. ® in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2(4):559-65.
31. Nakanishi T, Haruta T, Shirasaka Y, et al. Organic cation transporter-mediated renal secretion of ipratropium and tiotropium in rats and humans. Drug Metab Dispos. 2011;39(1):117-22.
32. ® in COPD patients [slide presentation]. In: European Respiratory Society Annual Congress 2013; 7-11 Sep 2013; Barcelona.
33. ®: comparison of bronchodilator efficacy of 5- and 2.5-μg doses [abstract no. P924 plus poster]. In: European Respiratory Society International Congress 2014; 6-10 Sep 2014; Munich.
34. Tang Y, Massey D, Zhong N-S. Evaluation of the efficacy and safety of tiotropium bromide (5 μg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease. Chin Med J. 2013;126(19):3603-7.
35. Wise RA, Anzueto A, Cotton D, et al. Tiotropium respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491-501.
36. ® improves physical functioning in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;5:367-73.
37. ® Soft Mist™ Inhaler in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:245-51.
38. Tashkin D, Metzdorf N, Hallmann C, et al. Safety of tiotropium in renally impaired patients [abstract no. P923 plus poster]. In: European Respiratory Society International Congress 2014; 6-10 Sep 2014; Munich.
39. Hohlfeld JM, Furtwaengler A, Könen-Bergmann M, et al. Cardiac safety of tiotropium in patients with COPD: combined analysis of Holter-ECG data from four randomized clinical trials [abstract no. P284 plus poster]. In: European Respiratory Society International Congress 2014; 6-10 Sep 2014; Munich.
40. ® (tiotropium bromide) inhalation spray for the maintenance treatment of COPD [media release]. 25 Sep 2014. http://us.boehringer-ingelheim.com/news-events/press-releases/press-release-archive/2014/09-25-14-boehringer-ingelheim-announces-fda-approval-spiriva-respimat-tiotropium-bromide-inhalation-spray-maintenance-treatment-copd.html.
41. Data on file, Boehringer Ingelheim: 2014.
42. Mathioudakis AG, Chatzimavridou-Grigoriadou V, Evangelopoulou E, et al. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent? Pulm Pharmacol Ther. 2014;28(2):91-7.
43. US Food and Drug Administration. Early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler). 2008. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070651.htm. Accessed 22 Sep 2014.
44. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439-50.
45. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-54.
46. US Food and Drug Administration. Follow-up to the October 2008 updated early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler). 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm197429.htm. Accessed 22 Sep 2014.
47. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med. 2009;103(10):1421-9.
48. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137(1):20-30.
49. ® in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis. 2009;4:397-409.
50. Bateman ED. Tiotropium Respimat increases the risk of mortality: con. Eur Respir J. 2013;42(3):590-3.
51. Singh S, Loke YK, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;342:d3215.
52. Dong Y-H, Lin H-H, Shau W-Y, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48-56.
53. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7: CD009285.
54. Verhamme KMC, Afonso A, Romio S, et al. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. Eur Respir J. 2013;42(3):606-15.
55. Disse B, Metzdorf N, Martin A, et al. Mortality associated with tiotropium mist inhaler? A critical appraisal of the authors' selection and use of previously communicated tiotropium Respimat data [letter]. 2011. http://www.bmj.com/content/342/bmj.d3215?tab=responses. Accessed 22 Sep 2014.
56. Metzdorf N, Hallmann C, Disse B. Thorax editorial by Jenkins and Beasley related to tiotropium respimat [letter]. Thorax. 2013;68(8):782.
57. Barnes NC, Jones PW, Davis KJ. Safety of tiotropium through the Handihaler: why did meta-analyses and database studies appear to give a false alarm? Thorax. 2014;69(6):598-9.
58. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC): PRAC minutes of the meeting on 2-5 December 2013. 2013. www.ema.europa.eu/docs/en-GB/document-library/Minutes/2014/01/WC500159614.pdf. Accessed 22 Sep 2014.
59. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC): minutes of the meeting on 5-8 May 2014. 2014. www.ema.europa.eu/docs/en-GB/document-library/Minutes/2014/06/WC500169468.pdf. Accessed 22 Sep 2014.
60. Verhamme KMC, Van Blijderveen N, Sturkenboom MCJM. Tiotropium and the risk of death in COPD [letter]. N Engl J Med. 2014;370(5):481-2.
61. ® in COPD: a safety analysis on pooled data [abstract]. In: American Thoracic Society 2014 International Conference; 16-21 May 2014; San Diego (CA).
62. ® [abstract no. P925 plus poster]. In: European Respiratory Society International Congress 2014; 6-10 Sep 2014; Munich.
63. Bateman ED. Improving inhaler use in COPD and the role of patient preference. Eur Respir Rev. 2005;14(96):85-8.
64. ® Soft Mist™ Inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1(3):251-9.
65. Fink JB, Colice GL, Hodder R. Inhaler devices for patients with COPD. COPD. 2013;10(4):523-35.
66. Beasley R. Tiotropium Respimat increases the risk of mortality: pro. Eur Respir J. 2013;42(3):584-9.
67. ® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. J Aerosol Med Pulm Drug Deliv. 2013;26(1):41-5.
68. Shah P, Dhurjon L, Metcalfe T, et al. Acute angle closure glaucoma associated with nebulised ipratropium bromide and salbutamol. BMJ. 1992;304(6818):40-1.
69. Oksuz H, Tamer C, Akoglu S, et al. Acute angle-closure glaucoma precipitated by local tiotropium absorption. Pulm Pharmacol Ther. 2007;20(6):627-8.
70. Hall SK. Acute angle-closure glaucoma as a complication of combined beta-agonist and ipratropium bromide therapy in the emergency department. Ann Emerg Med. 1994;23(4):884-7.
71. Boehringer Ingelheim. Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 2) [ClinicalTrials.gov identifier NCT02006732] US National Institutes of Health, ClinicalTrials.gov. 2014. http://www.clinicaltrials.gov/ct2/show/NCT02006732. Accessed 22 Sep 2014.
72. Boehringer Ingelheim. Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 1) [ClinicalTrials.gov identifier NCT01964352] US National Institutes of Health, ClinicalTrials.gov. 2014. http://www.clinicaltrials.gov/ct2/show/NCT01964352. Accessed 22 Sep 2014.
73. Derom E, Westerman J, Grönke L, et al. The 24-hour lung function profile of once-daily tiotropium and olodaterol fixed-dose combination compared with placebo and monotherapies in chronic obstructive pulmonary disease (VIVACITO) [poster]. In: American Thoracic Society International Conference; 16-21 May 2014; San Diego (CA).
74. Buhl R, Derom E, Ferguson G, et al. Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves ouctomes vs monocomponents in COPD in two 1-year studies [abstract no. 1895]. In: European Respiratory Society International Congress 2014; 6-10 Sep 2014; Munich.
75. ® in chronic obstructive pulmonary disease in two 1-year studies [poster]. In: European Respiratory Society International Congress 2014; 6-10 Sep 2014; Munich.
76. Yohannes AM, Connolly MJ, Hanania NA. Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis. 2013;8:117-25.